Recent Updates
Recently added Catalysts
MYO Positive Sentiment

Myomo Launches the MyoPro® 2x

Wednesday, April 30, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Myomo, Inc. has launched the MyoPro 2x, an advanced version of its MyoPro product line. This new device aims to improve arm and hand functionality for individuals suffering from upper-limb paralysis and neuromuscular conditions. The launch is seen as a major step forward in enhancing user independence.
Price reaction · baseline $4.63 (2025-04-29 close) · hit pre-market · 2 other MYO headline(s) in the window, move may be shared
day 0 close
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of MyoPro 2x enhances user independence.
  • Improves arm and hand function for individuals with paralysis.
  • Represents a significant advancement in wearable medical robotics.

Full Press Release Details

A Major Step Forward in Donning, Fit, and Function – Enhancing User Independence
BURLINGTON, Mass. – April 30, 2025 – Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers improved arm and hand function for individuals with upper-limb paralysis and neuromuscular conditions, today announced the launch of the MyoPro 2x, the latest evolution in its flagship MyoPro product line. Read more .

Frequently Asked Questions

What is the MyoPro 2x?

The MyoPro 2x is the latest version of Myomo's wearable device designed to improve arm and hand function.

Who can benefit from the MyoPro 2x?

Individuals with upper-limb paralysis and neuromuscular conditions can benefit from the MyoPro 2x.

What advancements does the MyoPro 2x offer?

The MyoPro 2x enhances user independence and improves the fit and function of the device.

When was the MyoPro 2x launched?

The MyoPro 2x was launched on April 30, 2025.

ShareAdd on Google
Tags: MYO Viatris Investor Conferences Healthcare Myomo MyoPro wearable robotics upper-limb paralysis neuromuscular conditions
Last updated: Apr 30, 2025

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~20 mo
Low dilution risk